Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sanofi’s Q3 China Revenues Increase at Slower 5% Rate

publication date: Oct 31, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sanofi’s global revenues dropped 6.7% to $11.6 billion in Q3, a disappointment. The company said a modest 2.8% increase in emerging markets sales was not enough to offset revenue shortfalls from drugs that have lost their patent protection. Sanofi’s China revenues actually rose during the quarter: they were up 5% to $477 million, though 5% represents a smaller increase than the double-digit percentage that has been the norm. More details....

Stock Symbol: (NYSE: SNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners